Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
LETTER TO THE EDITOR
Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse
1
Department of Hematology, Army Medical Center of PLA, Chongqing, China
These authors had equal contribution to this work
Submission date: 2026-05-16
Final revision date: 2026-07-19
Acceptance date: 2026-08-10
Online publication date: 2026-08-21
Corresponding author
TOPICS
REFERENCES (10)
1.
Bladé J, Beksac M, Caers J, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 2022; 12: 45.
2.
Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol 2016; 91: 575-80.
3.
Egan PA, Elder PT, Deighan WI, et al. Multiple myeloma with central nervous system relapse. Haematologica 2020; 105: 1780-90.
4.
Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022; 387: 495-505.
5.
Landry I, Binder AF, Yorker M, Ramirez S. Redefining central nervous system multiple myeloma: from rare phenomenon to emerging entity. Blood Rev 2025; 74: 101343.
6.
Zheng YH, Shen HY, Chen X, et al. Prognostic model and immune-infiltrating cell landscape based on differentially expressed autophagy-related genes in TP53-mutated multiple myeloma. Arch Med Sci 2021; 20: 1619-30.
7.
Katodritou E, Terpos E. Central nervous system myeloma: pathogenesis, diagnostic challenges, and practical management strategies. Hemasphere 2025; 9: e70213.
8.
Wang Y, Zu C, Teng X, et al. BCMA CAR-T therapy is safe and effective for refractory/relapsed multiple myeloma with central nervous system involvement. J Immunother 2022; 45: 25-34.
9.
Mutlu YG, Kaya SY, Maral S, et al. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. Front Immunol 2023; 14: 1276295.
10.
Noveihed A, Al Hadidi S, Mohan M, Shah MR. Bispecific antibody therapy in CNS myeloma: early evidence from a multicentre cohort. Br J Haematol 2025; 207: 2161-6.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
